Legacy CG’s Moderna MRNA Stock Holding History

Legacy CG’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-240	Closed	-$34K	–	100
2022 Q2	$34K	Buy	+240	New	+$34.3K	0.02%	71

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Legacy CG's MRNA Position: Q3 2022 in Review

Legacy CG sold out of Moderna (MRNA) in Q3 2022, closing a stake of 240 shares — an estimated $34K sold.

Legacy CG first reported a position in MRNA in Q2 2022 and held it in 1 quarter. The position peaked at $34K in Q2 2022. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

Legacy CG reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
Legacy CG sold 240 Moderna shares in Q3 2022, an estimated $34K.
Legacy CG first reported a position in Moderna in Q2 2022 and held it in 1 quarter.
Legacy CG's Moderna position peaked at $34K in Q2 2022.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Legacy CG's 13F filing for Q3 2022, filed 4 Nov 2022.